AMG-691
/ Amgen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 30, 2024
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
(clinicaltrials.gov)
- P1 | N=124 | Recruiting | Sponsor: Amgen | Not yet recruiting ➔ Recruiting
Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 1
Of
1
Go to page
1